458F
A Novel HBV Capsid Formation Inhibitor
That Additively Inhibits Virus Replication in
Combination with Tenofovir or IFN-α
Zhijun Zhang, Bo Liang, Yun-Yueh Lu and Huanming Chen,
Zhimeng Biopharma
Background: Currently approved drugs for chronic hepatitis
B do not provide a cure for the majority of patients. New
classes of direct antivirals that bring additive inhibitory effect
against HBV when used in combination with current drugs are
urgently needed.Methods: Medicinal chemistry and HepG2
cell-based assays were used for synthesizing, testing and
selecting small molecule compounds. Candidate compounds
were tested against HBV infection and HBsAg expression
in PHH assay.Results: We have discovered a novel series
of HBV capsid formation inhibitors (represented by CBHBV-
001) that is structurally distinctive from the current class
I (BAY-41-4109 as the prototype) and class II (represented
by AT-130) HBV capsid protein allosteric modulators. CBHBV-
001 promotes the formation of capsid devoid of HBV
pgRNA and DNA in a dose-dependent manner. CB-HBV-001
inhibits different genotypes of HBV strains and those that
are resistant to current NA HBV inhibitors. In addition, CBHBV-
001 inhibited HBV replication in a dose-dependent
fashion in a hydrodynamic-injection HBV mouse model. More
importantly, in PHH assay, CB-HBV-001 demonstrated an
additive effect with Tenofovir in inhibiting HBV DNA replication,
while it showed an additive effect with IFNa in inhibiting both
HBsAg and DNA. Conclusion: These characters of CBHBV-
001 plus its favorable PK and safety profiles in animal
models warrant its further development in clinical studies.
Disclosures:
Zhijun Zhang – ZhiMeng Biopharma: Employment 作者: StephenW 时间: 2018-10-23 15:44